NutriStack
What is happening. Coenzyme Q10 (ubiquinone) is frequently used by patients on cholesterol-lowering therapy because statins deplete endogenous CoQ10 synthesis. Bempedoic acid acts upstream of the mevalonate pathway at ATP-citrate lyase and, unlike statins, does not directly inhibit HMG-CoA reductase in muscle, so CoQ10 depletion and myopathy are far less of a concern. There is no pharmacokinetic interaction between CoQ10 and bempedoic acid.
Mechanism. Bempedoic acid inhibits cholesterol synthesis upstream of HMG-CoA reductase, theoretically able to reduce mevalonate-pathway products including ubiquinone, but its prodrug activation is largely confined to the liver (skeletal muscle lacks the activating enzyme ACSVL1), limiting muscle CoQ10 effects. Supplemental CoQ10 simply restores ubiquinone with no effect on bempedoic acid disposition.
Recommendation. CoQ10 can be taken safely alongside bempedoic acid. Its theoretical benefit is smaller than with statins because bempedoic acid is a prodrug activated mainly in the liver and is associated with low rates of muscle symptoms. Continue CoQ10 if it is already part of your regimen, but do not expect it to be necessary for muscle protection on bempedoic acid alone.